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Summary
Refining the functional groups on a phenethylamine
moiety within an inhibitor of HIV-1 protease led to a
switch in the mechanism of inhibition from competi-
tive and allosteric to dimerization inhibition. Phenyl-
ether extensions to the phenethylamine group led to
agents that target the dimerization interface of HIV-1
protease with high potency.
Introduction
HIV-1 protease (HIV-1 PR) exists as a homodimeric en-
zyme [1, 2] in which half of the active site and the sub-
strate binding site is found within each monomer [3, 4].
The primary function of HIV PR is site-specific cleavage
of the polypeptide products of the viral gag and gag-
pol genes [5]; without proper processing the virion re-
mains in an immature form [6–9]. As such, virions aris-
ing from transfection with a provirus mutated in the
protease coding region contained unprocessed viral
proteins and were noninfectious [8, 10, 11]. FDA-
approved agents that combat HIV infection through in-
hibition of the active site of HIV PR have been shown
to be potent in vivo [12, 13]. However, the effect is often
short lived as strains containing mutations around the
active site of HIV PR become more prevalent [14–16].
A potential alternative mode of inhibition would be to
target conserved elements of the virus, and an attrac-
tive target for such a strategy would be the dimerization
interface of HIV PR. A major portion of the stabilizing
interactions for dimerization is generated by a four-
stranded β sheet structure [17] that is formed by inter-
digitation of the C- and N-terminal residues of HIV PR.
The dimerization interface has been identified to be
highly conserved among HIV-1 isolates [18, 19]; pre-
sumably a mutation in any position (except Leu97)
would require a complementary mutation on the oppo-
site terminus of the enzyme to confer dimer stability.
In order to mimic the native structure of the con-
served β sheet region of HIV PR, a non-peptide-based
linker was used to connect the two N termini of the
interfacial peptides, leading to a dimerization inhibitor
(1) with good potency against HIV PR (Figure 1) [20].
Truncation of the interdigitating peptides and modifica-
tion of a tryptophan residue produced a lower molecu-
lar weight inhibitor (2) that also functioned by a dissoci-
ative mechanism [21]. The desire to reduce the number*Correspondence: chml@purdue.eduof amide linkages present in inhibitor 2 led to the re-
moval of the terminal carboxamide within the northern
tripeptide (compound 3, Figure 1), as our model sug-
gests that the carboxamide is not involved in hydrogen
bonding. The removal of the carboxamide would lead
to simplified diversity elements in this position based
on the phenethylamine group. Compound 3 was found
to be a modest inhibitor of HIV-1 PR with an IC50 value
of 5.8 M.
Results and Discussion
Although compound 3 was found to inhibit HIV-1 PR,
this agent did not act as a dimerization inhibitor using
the assay of Zhang and Poorman [22], despite being
equipotent to the dimerization inhibitor 2 (IC50 = 5.5 M,
Ki = 3.0 M), as nonparallel lines between the protease
in an inhibited and noninhibited form were obtained
(Figure 2A). In an effort to determine the mode of inhibi-
tion for compound 3, further assays were performed. A
double reciprocal Lineweaver-Burk plot for 3 with HIV-1
PR showed the intersection of the uninhibited and in-
hibited lines on the y axis, which is characteristic of a
purely competitive mechanism (Kc) of inhibition (Figure
2B). It seemed unlikely that 3 was acting by a traditional
mode of competitive, active site inhibition because it
lacks the heptapeptide structure associated with re-
cognition and active site binding [23] or the equivalent
tetrapeptide mimic required for active site inhibition
[24].
Competitive inhibition can manifest itself in several
forms and herein two variations are described. Classi-
cal competitive inhibition involves the inhibitor binding
to the active site of the enzyme thereby excluding the
substrate from the binding site. Alternatively, binding
to an allosteric site that alters the conformation of the
enzyme, leading to reduced affinity for the substrate,
can appear to be competitive inhibition. It is plausible
that the competitive inhibitor described is binding to
the β sheet target, but lacks the ability to either disrupt
the dimer or prevent dimer formation. Rather this agent
may cause a change in the substrate binding pocket
leading to reduced affinity for the substrate. In order to
distinguish between the two scenarios, we carried out
the crosscompetition assay as described by Yontani
and Theorell [25] to test whether 3 was binding to the
active site or to an allosteric site.
The crosscompetitive assay requires two inhibitors
that act by a purely competitive mechanism, whereby
the binding site of one of the inhibitors has been estab-
lished. Acetyl-pepstatin was chosen as one of the in-
hibitors for this assay since it has been shown to be a
competitive inhibitor of HIV-1 PR with Kc values of 20
nM and 35 nM at pH 4.7 and pH 5.0, respectively [26].
Additionally, the crystal structure of acetyl-pepstatin
with HIV-1 PR has been solved, demonstrating that the
location of binding is in fact the active site [27]. Due to
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440Figure 1. Structure of Compounds 1–3
See text for details.These data indicate that the effect of 3 binding toitive inhibitor 3 to HIV-1 PR in the presence of acetyl-
Figure 2. Inhibition Analysis of Compound 3
(A) Lineweaver-Burk double reciprocal plot for inhibitor 3 with 25 nM HIV-1 PR.C, uninhibited HIV PR;B, 6 M 3.
(B) Zhang-Poorman analysis for 3 (5–25 nM HIV-1 PR, 25 M substrate).B, uninhibited HIV PR;>, 6 M 3.
Error bars were obtained from an average of two trials.pH and ionic strength differences in the assay condi- p
ptions of Richards et al. and the conditions employed by
Chmielewski et al., it was necessary to assay acetyl- l
gpepstatin to determine the inhibitory constant for ensu-
ing calculations. Acetyl-pepstatin was found to be a t
acompetitive inhibitor of HIV-1 PR under our conditions
with a Kc value of 77 nM. After establishing acetyl- a
pepstatin as a viable competitive inhibitor of HIV-1 PR,
the crosscompetitive assay was performed using ace- b
ttyl-pepstatin and competitive inhibitor 3.
Nonexclusive binding can be shown in a Dixon plot a
tof 1/v versus [3] for multiple constant concentrations
of acetyl-pepstatin or 1/v versus [acetyl-pepstatin] for e
dmultiple constant concentrations of 3. The slope of this
plot will depend on the concentration of the varying in- b
ohibitor as described by Yonetani and Theorell [25]. Con-
sequently, the data obtained at different fixed concen- d
ttrations of one inhibitor and varied second inhibitor
concentrations will not be parallel if synergistic binding f
tis occurring. A crosscompetitive experiment was per-
formed to evaluate the nature of the binding of compet- depstatin (Figure 3A), as well as acetyl-pepstatin in the
resence of 3 (Figure 3B). In each case, nonparallel
ines were obtained indicating simultaneous and syner-
istic binding. These data provide evidence that inhibi-
or 3 is not binding to the active site of the enzyme
s with acetyl-pepstatin, but is acting by binding to an
llosteric site.
One may also obtain information on the effect of
inding of one inhibitor or the simultaneous binding of
he second inhibitor by using the method of Yontani
nd Theorell to obtain α—the constant defining the in-
eraction between the two inhibitors. The value of α will
qual 1 if binding of the two inhibitors occurs indepen-
ently, <1 if the binding of one inhibitor facilitates the
inding of the second inhibitor, and >1 if the binding of
ne inhibitor makes the binding of the second more
ifficult. An infinite α value indicates that the two inhibi-
ors bind in a mutually exclusive manner and compete
or the same binding site. Calculating the α value from
he Dixon plots, the α value for acetyl-pepstatin was
etermined to be 0.05 and the α value for 3 was 140.
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441Figure 3. Yonetani-Theorell Inhibition Analysis of Compound 3
(A) Yonetani-Theorell plot of v/vi versus concentration of compound 3 in systems containing constant acetyl-pepstatin concentrations. C, 0
nM acetyl-pepstatin;B, 72 nM acetyl-pepstatin; ;, 109 nM acetyl-pepstatin; 7, 145.5 nM acetyl-pepstatin. (25 nM HIV-1 PR, 12.5 M sub-
strate).
(B) Yonetani-Theorell plot of v/vi versus concentration of acetyl-pepstatin in systems containing constant concentrations of compound 3.C,
0 M compound 3;B, 4 M compound 3;P, 6 M compound 3; ;, 8 M compound 3 (25 nM HIV-1 PR, 12.5 M substrate).
Error bars were obtained from an average of two trials.HIV-1 PR has a positive impact on the binding of acetyl-
pepstatin, perhaps due to a change in the substrate
recognition site of HIV-1 PR, as the Km(app) of HIV-1
PR,3 is increased by definition as a competitive inhibi-
tor. On the other hand acetyl-pepstatin binding has the
opposite effect on the binding of 3. This may be due to
the cooperative stabilization of residues at the dimeric
interface caused by the binding of acetyl-pepstatin to
the active site, thereby reducing the ability of 3 to po-
tentially bind in this region [28].
Many phenethylamine derivatives are known, and this
provided the possibility to prepare a small library of
agents based on the core structure of 3, but with modi-
fications to the terminal phenyl ring (Figure 4A). A solu-
tion-based strategy was used for the synthesis of seven
analogs, utilizing a Cbz-protected dipeptide (Z-Thr
(Ot-Bu)-Leu-OH) for reaction with the phenethylamine
derivatives. Various phenethylamine derivatives were
reacted with this invariant dipeptide to generate the de-
sired amide, followed by reaction with Asn-Phe(Ot-Bu)
and the di-N-hydroxysuccinimide ester of hexadec-
anodioic acid to provide the desired target molecules
after treatment with TFA. Several exceptions to the
general synthesis were required due to variable func-
tionality of ring. In most cases, the removal of the Cbz
protecting group was affected by hydrogenation to pro-
vide the desired northern fragments. The synthesis of
the desired tripeptide containing an –OH in the R2 posi-
tion was completed by the use of BBr3 [29] to convert
the methoxy group of the tripeptide to a hydroxyl group
while simultaneously removing the protecting groups.
The potency of compounds 4–10 against HIV-1 PR
was initially determined using the fluorogenic assay de-
veloped by Toth and Marshall (Figure 4C) [30]. Substitu-
tions to the phenyl ring in the meta-position (R2) of a
hydroxyl group (4) or a methoxy group (5) had little ef-
fect on the potency of these compounds, and kinetic
analyses (Zhang Poorman and Lineweaver Burk) con-
firmed a competitive inhibition mechanism. Interest-ingly, substitition at the para-position (R1) with a hy-
droxyl group (6) provided no increase in potency, but
neither purely dimerization nor competitive inhibition
was observed. Instead, this compound was found to
be a mixed type inhibitor by Lineweaver-Burk analysis.
The methoxy compound (7), however, was approxi-
mately 2-fold more potent than 6, and was found to
inhibit HIV-1 PR as a dimerization inhibitor by Zhang
Poorman analysis (Figure 4B). Similarly, an amino group
was well accommodated in the dimerization inhibitor
10. Combining the two hydroxyl groups by using the
dopamine analog 8 did not increase potency over com-
pound 7, although the dissociative mechanism of inhi-
bition was maintained, whereas the bis-methoxy deriv-
ative 9 lost potency and a mixed type of inhibition
was observed.
These data confirmed that increased potency could
be obtained by substitution at the para-position of in-
hibitor 3, and that the allosteric mechanism of inhibition
may be switched to a dissociative mechanism by small
modifications. The successful addition of the methyl
group in inhibitor 7, and the increased potency observed
with phenyl ether substitution in northern peptide of
compound 2 [31] led to the synthesis of two additional
analogs (11, 12) with phenyl ether functionality at posi-
tion R1 (Figure 5A). The synthesis of the desired biphe-
nyl ethers was accomplished as described above.
However, the phenol functionality of tyramine was re-
acted with a copper activated aryl boronic acid [32, 33],
to produce Cbz-(4-(4-methoxyphenoxy)-tyramine, which
was simultaneously deprotected and the methoxy group
was converted to a hydroxyl group using BBr3 [29].
Compounds 11 and 12 were potent inhibitors of HIV-1
PR with IC50 values in the high nM range (Figure 5C). A
Zhang-Poorman analysis provided evidence for dimer-
ization inhibition (Figure 5B) and provided Ki values that
are close to some of the most potent dimerization in-
hibitors reported to date [31, 34]. Compound 12 (Ki =
96 nM) is nearly twice as potent as 11 (K = 175 nM),i
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442Figure 4. Inhibition Analysis of Compounds 4–10
(A) Structural data for compounds 4–10. (B) Zhang-Poorman assay of compounds 7, 8, and 10. B, uninhibited HIV-1
PR; $, 1.6 M compound 7; 6, 2.9 M compound 8; 7, 1.4 M compound 10 (3–36 nM HIV-1 PR, 25 M substrate). (C) Kinetic data for
compounds 4–10. Error bars were obtained from an average of two trials.whereas these agents are approximately 15- and 30- m
dfold more potent, respectively, than 2. This increased
potency may be due to the presence of the biaryl ether residues. In this binding orientation the extended aro-
Figure 5. Inhibition Analysis of Compounds 11 and 12
(A) Structural data for compounds 11 and 12. (B) Zhang-Poorman assay of compounds 11 and 12. B, uninhibited HIV-1 PR; 6, 660 nM
compound 11; 7 500 nM compound 12 (3–36 nM HIV-1 PR, 25 M subs
obtained from an average of two trials.oiety binding on the surface of HIV-1 PR in a hy-
rophobic pocket in close proximity to polar, unchargedtrate). (C) Kinetic data for compounds 11 and 12. Error bars were
Allosteric and Dimerization Inhibitors of HIV PR
443matic ring also brings the hydroxyl group of 12 in close
proximity to Asp29, Gln92, and Asn88 of HIV-1 PR ac-
cording to our model (Figure 6).
Significance
Herein we describe an inhibitor (3) of HIV-1 protease
(HIV-1 PR) that functions by allosteric binding, a
mode of inhibition that may be more effective than
dimerization inhibition in cases of high substrate con-
centration. Small modifications to the phenethyl-
amine portion of compound 3 led to significant in-
creases in potency, and, interestingly, a switch in the
mechanism of inhibition against HIV-1 PR from allo-
steric to dimerization inhibition. This class of inhibi-
tors provides a more easily modified system for the
synthesis of extended aromatic groups than pre-
viously reported compounds with a terminal amino
acid, and may lead to a new source for the generation
of potent inhibitors.
Experimental Procedures
Fluorescence-Based Kinetic Assay
All solutions were transferred using siliconized low retention pi-
pette tips (Fischer). 1.2 ml polypropylene tubes were used for incu-
bation of the inhibitor and HIV-1 PR prior to addition to substrate.
The substrate was added to a polypropylene fluorescence 96-well
plate (Greigner) prior to addition of the inhibited and uninhibited
HIV-1 PR samples. The change in fluorescence was measured at
430 nm (λex = 355 nm) for 20 min at 30°C, using a Tecan SPECTRA-
Fluoro Plus 96-well plate reader. Raw kinetic data was imported into
Microsoft Excel, converted to the appropriate format, and plotted.
2Figure 6. A model of the biphenylether portion of compound 12
bound to the protease monomer.
See text for details.Slope, y-intercept, and R values were determined by linear regres-
sion. Resultant data was plotted in SigmaPlot to display error bars.Determination of IC50 Values Using Fluorogenic Assay
A solution of 180 l of 50 nM HIV-1 protease in buffer (20 mM
phosphate, 1 mM DTT, 1 mM EDTA, 20% glycerol, and 0.1%
CHAPS at pH 5.52; final concentration 25 nM protease) was incu-
bated with 36 l of the appropriate concentration of inhibitor solu-
tion in DMSO for 1 hr at room temperature. 60 l of this solution
was added to 40 l of a 150 M substrate solution (final concentra-
tion 60 M), and the fluorescence was measured. The change in
fluorescence values was compared to sample containing no in-
hibitor.
Determination of Kd and Ki Using the Zhang-Poorman Assay
Solutions of 180 l of various concentrations of HIV-1 protease in
buffer (20 mM phosphate, 1 mM DTT, 1 mM EDTA, 20% glycerol,
and 0.1% CHAPS at pH 5.52; final concentration 3-36 nM protease)
were incubated with 36 l of each inhibitor solution (concentra-
tion = IC50 value and 0.75 × IC50 value) in DMSO for 1 hr at room
temperature. 60 l of this solution was added to 40 l of a 62.5 M
substrate solution (final concentration 25 M), and the fluores-
cence was measured. Values obtained from the kinetic cleavage of
the protease substrate were converted to mol/sec cleaved using
a response curve (full cleavage of various substrate concentrations
versus relative fluorescence units). The initial velocity of the prote-
ase was used (<5% substrate consumed). The concentration of
HIV-1 protease divided by the square root of the converted slopes
was plotted versus the square root of the converted slopes.
Determination of Km and Kc Using Double-Reciprocal Plots
Solutions of 180 l of HIV-1 protease in buffer (20 mM phosphate,
1 mM DTT, 1 mM EDTA, 20% glycerol, and 0.1% CHAPS at pH 5.52;
final concentration 25 nM protease) were incubated with 36 l of
each inhibitor solution (concentration = IC50 value) in DMSO for 1
hr at room temperature. 60 l of this solution was added to 40 l
of a 2.5–30 M substrate solution and the fluorescence was mea-
sured. Values obtained from the kinetic cleavage of the protease
substrate were converted to mol/sec cleaved using a response
curve (full cleavage of various substrate concentrations versus rel-
ative fluorescence units). The initial velocity of the protease was
used (<5% substrate consumed). The inverse of the initial velocity
was plotted versus the inverse of the substrate concentration.
Determination of Crosscompetitive Inhibition
Solutions of 180 l of HIV-1 protease in buffer (20 mM phosphate,
1 mM DTT, 1 mM EDTA, 20% glycerol, and 0.1% CHAPS at pH 5.52;
final concentration 25 nM protease) were incubated with 36 l of
each inhibitor solutions varying in the concentration of a known
active site competitive inhibitor (pepstatin-(0–100.8 nM) with con-
stant concentrations of compound 2 (0, 4, 6, 8 M) in DMSO for 1
hr at room temperature. Alternatively, solutions of 180 l of HIV-1
protease in buffer (20 mM phosphate, 1 mM DTT, 1 mM EDTA, 20%
glycerol, and 0.1% CHAPS at pH 5.52; final concentration 25 nM
protease) were incubated with 36 l of each inhibitor solutions a
constant concentration of a known active site competitive inhibitor
(pepstatin, 72, 109, 145 nM) with varying concentrations of com-
pound 2 (0–10 M) in DMSO for 1 hr at room temperature. 60 l of
this solution was added to 40 l of a 30 M substrate solution and
the fluorescence was measured. Values obtained from the kinetic
cleavage of the protease substrate were converted to mol/sec
cleaved using a response curve (full cleavage of various substrate
concentrations versus relative fluorescence units). The inverse of
the initial velocity was plotted versus the concentration of the vary-
ing competitive inhibitor.
Supplemental Data
A list of the compound characterizations is available online at
http://www.structure.org/cgi/content/full/12/4/439/DC1/.
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